HER2 and HER3 mutations were widely spread through the whole exome of both genes (Fig 3C and 3D); two of the HER2 mutations are located in the kinase domain (one patient with intrahepatic cholangiocarcinoma and a second patient with gallbladder cancer) (Fig 3C); none of the HER3 mutations were located in kinase domain; two were located in the receptor L domain (site of ligand binding) (Fig 3D). Here, ERBB2 is linked to intrahepatic cholangiocarcinoma.